Fortrea (FTRE) Q2 2024 earnings summary

Executive summary

• Q2 2024 revenue was $662.4 million, down 8.6% year-over-year, with a GAAP net loss of $99.3 million and adjusted EBITDA of $55.2 million, which more than doubled sequentially from Q1 2024.

• Adjusted EBITDA margin was 8.3%, down from 9.9% in Q2 2023, and adjusted net loss was $2.3 million versus adjusted net income of $46.1 million last year.

• The company completed divestitures of Endpoint Clinical, Patient Access, and Enabling Services, using proceeds to pay down $504 million in debt and improve capital structure.

• Book-to-bill ratio for Q2 was 0.96x, with a trailing twelve-month ratio of 1.16x and backlog of $7.4 billion, up 5.6% since the spin.

• Exited 60% of Transition Services Agreements with the former parent by end of Q2 2024, with most remaining exits planned by year-end.

Financial highlights

• Q2 2024 revenues were $662.4 million, down from $725.1 million in Q2 2023; first half 2024 revenues were $1,324.5 million, down from $1,419.0 million.

• Adjusted EBITDA was $55.2 million (8.3% margin), down from $71.9 million (9.9% margin) in Q2 2023.

• Net loss for Q2 2024 was $99.3 million, compared to net income of $25.0 million in Q2 2023; adjusted net loss was $2.3 million.

• Free cash flow for the first half of 2024 was $227.6 million, up from $122.3 million in the prior year period.

• Cash and cash equivalents stood at $126.2 million as of June 30, 2024, with gross debt at $1,142.0 million.

Outlook and guidance

• Full-year 2024 revenue guidance lowered to $2,700–$2,750 million, with adjusted EBITDA guidance at $220–$240 million.

• Targeting Q4 2024 adjusted EBITDA margin of 11–12%, with 2025 margin also expected in this range and a 30–40% increase in adjusted EBITDA dollars year-over-year.

• Management expects to comply with all debt covenants for at least the next 12 months and believes liquidity is sufficient for operations.

• Guidance reduction reflects lower pass-through and service-fee revenues and lower net new business in H1 2024.

• Anticipates return to positive cash flow in 2025 as separation costs subside.